Product Description: Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076.
CAS Number: 2734715-10-5
Molecular Weight: N/A
Compound Purity: 96.34
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related